The Efficacy of Teriparatide in Improving Fracture Healing in Hip Fractures: A Systematic Review and Meta-Analysis

Table 1

Summary of the included studies.

Study ID	Design	Diagnosis	No. of patients		Age		Primary treatment	Medical treatment		Outcome measures	Follow-up
			Teriparatide	Control	Teriparatide	Control		Teriparatide	Control
Bhandari 2016	RCT	Femoral neck fracture	78	81	70 (50–94)	70 (50–90)	ORIF	20 μg, once daily for 6 months	Placebo, identical device	Reoperation, fracture healing, pain, complications, adverse events, death, and deformity	12 months
Chesser 2016	RCT	Trochanteric fracture	15	14			ORIF	20 μg, once daily for 6 weeks	Standard control	Death, complications, and fracture healing	3 months
Huang 2015	Retrospective study	Pertrochanteric fractures	31	50			ORIF	20 μg, once daily for 18 months	Without receiving teriparatide	Death, reoperation, pain, complications, fracture healing, subsequent fracture, and HHS	40.1 months
Huang 2016	Retrospective study	Intertrochanteric fractures	47	83			ORIF	20 μg, once daily for 18 months	Without receiving teriparatide	Fracture healing, complications, death, reoperation, and subsequent fracture	12 months
Kim 2018	Retrospective study	Intertrochanteric fractures	46	50	81.6 (65.8-97.9)	82.3 (67.1-99.3)	ORIF	56.5 μg, weekly for 8 weeks	Without receiving teriparatide	HHS, pain, fracture healing, complications, reoperation, and deformity	6 months
Kim 2019	Retrospective study	Intertrochanteric fractures	52	60	81.4 (66.2-97.9)	80.2 (67.1-99.3)	ORIF	20 μg, once daily for 2 months	Without receiving teriparatide	HHS, pain, fracture healing, complications, reoperation, and deformity	19 months